Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?

Gastroenterology

Volumn 142, Issue 6, 2012, Pages 1356-1359

  Feld, Jordan J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

DAA; direct acting antivirals; HCV; hepatitis C virus; interferon stimulated genes; ISG; protease inhibition for viral evaluation 2; protease inhibition for viral evaluation 3; PROVE 2; PROVE 3; serine protease inhibitor therapy 1; SPRINT 1

Indexed keywords

BOCEPREVIR; GS 9256; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ENZYME INHIBITION; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TH1 CELL; VIRAL CLEARANCE;

EID: 84860311258     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.12.064     Document Type: Article

References (25)

1. J.G. McHutchison, M.P. Manns, A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
2. C.F.N. Hézode, G. Dusheiko, P. Ferenci Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1827 1838
3. P.Y. Kwo, E.J. Lawitz, J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
4. J.J. Feld, J.H. Hoofnagle Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 2005 967 972
5. J.G. McHutchison, M.L. Shiffman, R.C. Cheung A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-α in previously untreated patients with chronic hepatitis C Antivir Ther 10 2005 635 643
6. D. Maag, C. Castro, Z. Hong Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin J Biol Chem 276 2001 46094 46098
7. J.M. Pawlotsky, H. Dahari, A.U. Neumann Antiviral action of ribavirin in chronic hepatitis C Gastroenterology 126 2004 703 714
8. K.C. Young, K.L. Lindsay, K.J. Lee Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy Hepatology 38 2003 869 878
9. W.P. Hofmann, T.L. Chung, C. Osbahr Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir Antivir Ther 16 2011 695 704
10. F. Rahman, T. Heller, Y. Sobao Effects of antiviral therapy on the cellular immune response in acute hepatitis C Hepatology 40 2004 87 97
11. N.M. Dixit, J.E. Layden-Almer, T.J. Layden Modelling how ribavirin improves interferon response rates in hepatitis C virus infection Nature 432 2004 922 924
12. S. Crotty, C.E. Cameron, R. Andino RNA virus error catastrophe: direct molecular test by using ribavirin Proc Natl Acad Sci U S A 98 2001 6895 6900
13. T. Kanda, O. Yokosuka, F. Imazeki Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA J Viral Hepat 11 2004 479 487
14. S. Chevaliez, R. Brillet, E. Lazaro Analysis of ribavirin mutagenicity in human hepatitis C virus infection J Virol 81 2007 7732 7741
15. J.J. Feld, S. Nanda, Y. Huang Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response Hepatology 46 2007 1548 1563
16. E. Thomas, J.J. Feld, Q. Li Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models Hepatology 53 2011 32 41
17. J.J. Feld, G.A. Lutchman, T. Heller Ribavirin improves early responses to peginterferon through improved interferon signaling Gastroenterology 139 2010 154 162 e4
18. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
19. S. Zeuzem, P. Buggisch, K. Agarwal The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C Hepatology 55 2012 749 758
20. S. Zeuzem, T. Asselah, P. Angus Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV Infection Gastroenterology 141 2011 2047 2055
21. J.T. Nguyen, J.D. Hoopes, M.H. Le Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro PLoS One 5 2010 e9332
22. E.J.S.C. Gane, R.H. Hyland, R.D. Sorensen Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-nave patients with HCV GT2 or GT3 (abstract) Hepatology 54 2011 34
23. K.T.S. Chayama, Y. Kawakami, K. Ikeda Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders (abstract LB4) Hepatology 54 2011
24. L. Rong, H. Dahari, R.M. Ribeiro Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30 32
25. J.H. Hoofnagle, M.G. Ghany, D.E. Kleiner Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin Hepatology 38 2003 66 74